ArticleMolecular cancer therapeutics2016

Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling.

László G Puskás et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.